Pembrolizumab is the first drug approved by the U.S. Food and Drug Administration for use based on a biomarker (a specific genetic feature) rather than the location in the body where the tumor originated. The drug is indicated [more]
May was awash with news stories about blood tests for prostate cancer. Reports that a new serum test called IsoPSA could predict prostate cancer more precisely than conventional PSA testing brought obvious interest. The new [more]
According to an analysis just published on American Cancer Society’s CA: A Cancer Journal for Clinicians, rare cancers account for almost a fifth of all new diagnoses, and up to over two thirds of all new diagnoses [more]
An ESO task force met to discuss the potential for “biosimilar” medical products in oncology, analyzing facts and debunking some myths. Some of the most used biologic drugs in oncology are going off patent in [more]
ESO’s brochure “Who’s Who and Programmes 2017” is now available (click on the image to download the pdf).
Ne umquam pars pro toto (Plinius). Can anyone remember a bit of Latin? This quotation was used in a slide presentation given a few weeks ago by Louis Denis, urologist and prostate cancer patient, at [more]
Uncontrolled pain can blight the lives of cancer patients and survivors. But all too often, health professionals don’t ask, and patients don’t tell. Simon Crompton looks at why this is still the case, and what [more]
Lung cancer kills more people in Europe than any other type of cancer, yet efforts to monitor and improve standards of treatment and care have lagged behind those of less fatal cancers, such as breast [more]
Complex healthcare cannot succeed without effective communication between everyone involved in the patient’s care, with each understanding and respecting the contribution of others. Peter McIntyre looks at where things can go wrong, and how to [more]
A chance to work at the heart of the trailblazing MINDACT trial gave Ivana Božović-Spasojević a memorable lesson in the value of international academic trials, and the logistics of how to run them. She spoke [more]
With studies showing that around half of all cancer patients use therapies that are not part of mainstream medicine, Cancer World Editor Alberto Costa explores some aspects of the discussion on what complementary and integrative [more]
Sriram Venneti and colleagues examine non-invasive metabolic imaging strategies that can be used to interrogate some of the genomic alterations in brain tumours, with the ultimate goal of informing patient management. This is an abridged [more]
Male breast cancer is almost always oestrogen receptor positive, and is traditionally treated in line with guidelines for treating hormone-sensitive breast cancers in postmenopausal women. Ian Fentiman questions the rationale for this approach, pointing to [more]